1. Home
  2. SCOR vs NYXH Comparison

SCOR vs NYXH Comparison

Compare SCOR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

N/A

Current Price

$6.45

Market Cap

112.4M

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$2.86

Market Cap

134.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
NYXH
Founded
1999
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Business Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
134.5M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
SCOR
NYXH
Price
$6.45
$2.86
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
9.7K
31.1K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
N/A
EPS
N/A
N/A
Revenue
$403,549,000.00
N/A
Revenue This Year
$2.75
$213.98
Revenue Next Year
$7.30
$126.25
P/E Ratio
$1.55
N/A
Revenue Growth
1.02
N/A
52 Week Low
$4.39
$2.72
52 Week High
$10.18
$8.59

Technical Indicators

Market Signals
Indicator
SCOR
NYXH
Relative Strength Index (RSI) 40.29 42.34
Support Level $6.22 $2.80
Resistance Level $7.07 $3.36
Average True Range (ATR) 0.38 0.16
MACD -0.07 -0.02
Stochastic Oscillator 20.38 22.22

Price Performance

Historical Comparison
SCOR
NYXH

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: